Home > Insider Trading > Filing (0000899243-19-022047)

Filing Details

Accession Number:: 0000899243-19-022047
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-08-19 16:35:47
Reporting Period:: 2019-08-15

Accepted Time:: 2019-08-19 16:35:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1654151	Deciphera Pharmaceuticals Inc.	DCPH	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1625653	New Leaf Ventures Iii, L.p.	C/O New Leaf Ventures 420 Lexington Avenue, Suite 408 New York NY 10170	No	No	Yes	No
1625656	New Leaf Venture Associates Iii, L.p.	C/O New Leaf Ventures 420 Lexington Avenue, Suite 408 New York NY 10170	No	No	Yes	No
1625657	New Leaf Venture Management Iii, L.l.c.	C/O New Leaf Ventures 420 Lexington Avenue, Suite 408 New York NY 10170	No	No	Yes	No
1625693	New Leaf Bpo Associates I, L.p.	C/O New Leaf Ventures 420 Lexington Avenue, Suite 408 New York NY 10170	No	No	Yes	No
1625696	New Leaf Biopharma Opportunities I, L.p.	C/O New Leaf Ventures 420 Lexington Avenue, Suite 408 New York NY 10170	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-08-15	71,550	$36.09	1,886,282	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-08-16	69,292	$36.54	1,816,990	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-08-16	26,108	$37.01	1,790,882	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-08-15	78,450	$36.09	2,067,858	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-08-16	75,974	$36.54	1,991,884	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-08-16	28,626	$37.01	1,963,258	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
The reportable securities are owned directly by New Leaf Ventures III, L.P. ("NLV III"). New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
(Continuation from footnote 2) Each of Ronald M. Hunt and Vijay K. Lathi (each, a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
(Continuation from footnote 6) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.